<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01609959</url>
  </required_header>
  <id_info>
    <org_study_id>12-Ken-001</org_study_id>
    <nct_id>NCT01609959</nct_id>
  </id_info>
  <brief_title>New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure Lowering</brief_title>
  <acronym>NARA</acronym>
  <official_title>Effects of the New Angiotensin II Receptor Blocker Azilsartan Versus Valsartan on Blood Pressure in Japanese Patients With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nara Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nara Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare blood pressure lowering effect of azilsartan with
      that of valsartan in Japanese patients with hypertension who have already taken normal-dose
      angiotensin II receptor blockers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertension plays a major role in the development of cardiovascular disease. Several
      guidelines require strict control of blood pressure for preventing cardiovascular events;
      however, the control is often poor.

      A new angiotensin II receptor blocker (ARB), azilsartan, is the first drug which is superior
      to other ARBs in blood pressure lowering in phase III clinical trials in Japan. We try to
      evaluate effect of azilsartan on blood pressure lowering in Japanese patients with
      hypertension who have already taken normal-dose ARBs, and to compare it with that of
      valsartan.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Office Blood Pressure</measure>
    <time_frame>Baseline and every 2 weeks (up to 12 weeks)</time_frame>
    <description>Change in blood pressure measured at a clinic</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Home Blood Pressure</measure>
    <time_frame>Baseline and every 2 weeks (up to 12 weeks)</time_frame>
    <description>Change in blood pressure measured at home
Blood pressure is measured twice daily in the morning fasting before taking any drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Renal Function</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Changes in levels of serum creatinine and proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Triglyceride</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glycemic Control</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Changes in levels of fasting blood glucose, hemogrobin A1C and fasting insulin (if needed)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Aldosterone Concentration</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Only in patients with secondary hypertension</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Azilsartan group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan</intervention_name>
    <description>Azilsartan 20 mg or 40 mg (if blood pressure does not reach the target after 6 weeks) per day for 12 weeks</description>
    <arm_group_label>Azilsartan group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>Valsartan 160 mg per day</description>
    <arm_group_label>Valsartan group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hypertensive patients treated with normal-dose angiotensin II receptor blockers (ARBs)
             in Japan

          -  Normal-dose ARBs in Japan are defined as follows: losartan potassium 50 mg,
             candesartan cilexetil 8 mg, valsartan 80 mg, telmisartan 40 mg, olmesartan medoxomil
             20 mg, or irbesartan 100mg per day.

        Exclusion Criteria:

          -  Hypersensitivity for azilsartan and valsartan

          -  Pregnant female

          -  History of azilsartan use within 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoshihiko Saito, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Department of Internal Medicine, Nara Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Department of Nara Medical University</name>
      <address>
        <city>Kashihara</city>
        <state>Nara</state>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2012</study_first_submitted>
  <study_first_submitted_qc>May 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2012</study_first_posted>
  <last_update_submitted>October 28, 2013</last_update_submitted>
  <last_update_submitted_qc>October 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nara Medical University</investigator_affiliation>
    <investigator_full_name>Yoshihiko Saito</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Angiotensin II Receptor Blocker</keyword>
  <keyword>Azilsartan</keyword>
  <keyword>Valsartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Angiotensinogen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

